Latest Decongestants Stories

JERUSALEM, Sept. 22 /PRNewswire-FirstCall/ -- IDenta Corp., (Other OTC: IDTA) today released the results of the reports conducted by Two famous French agencies. The two French agencies conducted a comprehensive tests on some of Identa products. The tests and the results are listed below. The French agency National Institute of Forensic Science (INPS) and the Laboratory of Forensic Science of Lyon (LPS)Drugs Section recently conducted a STUDY OF KITS FOR THE DETECTION OF TATP/HMTD IDENTA ON...

- TV Host Explains How Talking to a Pharmacist Helped Her Manage Her Congestion so She Can Get Back to Her Busy Schedule - WASHINGTON, D.C., April 2 /PRNewswire/ -- Mom, actress and allergy sufferer Alison Sweeney knows first hand how symptoms like congestion can make juggling a busy career and family life even more challenging. That's why she's teamed up with the American Pharmacists Association (APhA) and McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. to launch Behind the...

- Safe Driving Pledge Unveiled as Part of Nationwide Awareness Campaign - KENILWORTH, N.J., March 18 /PRNewswire-FirstCall/ -- This spring allergy season, Schering-Plough (NYSE: SGP), maker of the non-drowsy allergy medicine, CLARITIN, is continuing its partnership with allergy sufferer and NASCAR driver Carl Edwards to encourage safe driving practices. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/claritin/37512/ "Drowsy driving is dangerous so I'm...

- Partnership Drives Home Importance of Being Alert and Focused on and off the Racetrack - KENILWORTH, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP), maker of the top-selling allergy medicine, CLARITIN, announces its second Sprint Cup racing season as a sponsor of NASCAR star and long-time allergy sufferer Carl Edwards. Edwards, who takes non-drowsy CLARITIN to treat his allergy symptoms, will drive the No. 99 CLARITIN Ford Fusion during the April NASCAR Sprint Cup...

BOTHELL, Wash., Jan. 20 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today announced that the U. S. Food and Drug Administration (FDA) has issued a Complete Response letter for its Abbreviated New Drug Application (ANDA) for pseudoephedrine. The application, filed by SCOLR on August 5, 2008, seeks approval to market a 120 mg 12 hour pseudoephedrine tablet based on its patented Controlled Delivery Technology (CDT(R)) platform. The Complete Response letter requests additional...

- Introducing the First and Only Non-Drowsy Allergy Medicine in a Liquid-Filled Capsule - KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announces the introduction of new CLARITIN(R) Liqui-Gels(R), the first and only non-drowsy allergy medicine in an easy-to-swallow liquid-filled capsule. Now available over-the-counter, CLARITIN(R) Liqui-Gels(R) provide powerful liquid relief for the worst allergy symptoms without causing drowsiness....

WASHINGTON, Jan. 12 /PRNewswire-USNewswire/ -- Rite Aid Corporation (Rite Aid) and nine of its subsidiaries in eight states have agreed to pay $5 million in civil penalties to settle allegations of violations of the Controlled Substances Act (CSA), the Department of Justice announced today. In addition to the $5 million penalty, Rite Aid and all of its subsidiaries agreed to a compliance plan with the U.S. Drug Enforcement Administration (DEA) to ensure compliance with all requirements of...

HARBIN, China, Dec. 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that its wholly-owned subsidiary, Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), obtained production approval from the State Food and Drug Administration ("SFDA") in China for a new nasal drop for...

Researchers from Boston University's Slone Epidemiology Center have found that exposure to pseudoephedrine, a decongestant found in many cough-and-cold and allergy medications, has been common among U.S. children, especially those under the age of two years who are at the highest risk for toxicity and for whom safe dosing recommendations are lacking. These findings appear in the December issue of the journal Pediatrics.Pseudoephedrine has been associated with deaths and adverse events in...

Scolr Pharma, a specialty pharmaceutical company, has announced that the FDA has accepted for review the company's abbreviated new drug application for a 120mg 12-hour pseudoephedrine tablet based on its patented controlled delivery technology platform. The abbreviated new drug application (ANDA) was submitted to the FDA on August 5, 2008. This is said to be the first application filed by Scolr Pharma with the FDA. Pseudoephedrine is a decongestant that is an active ingredient in Allegra...